🇺🇸 FDA
Pipeline program

TAK-442

TAK-442_202

Phase 2 small_molecule completed

Quick answer

TAK-442 for Acute Coronary Syndrome is a Phase 2 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Acute Coronary Syndrome
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials